TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02251392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomila recutita Gel
Description: Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomila recutita Infuse
Description: chamomila infuse in a concentration of 2,5% already determined in a dose response curve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea cream based
Description: Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
Study: NCT02448082

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shampoo (inactive)
Description: Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium shale oil sulponate 1% shampoo
Description: Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
Study: NCT04241523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 4 mg Oral
Description: Planned doses of 8 mg of lenvatinib per day for patients with body weight \<60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed.
Study: NCT03458091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Oxygenation during apnea using transversal humidified oxygen
Study: NCT03458091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
Study: NCT04491994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
Study: NCT04410679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injectable PRF
Description: blood sample and centrifuged to obtain i-PRF
Study: NCT00561353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
Study: NCT05616897

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physiological responses during sustained CPR

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physiological responses during sustained CPR
Study: NCT00561353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
Study: NCT01375920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a matched placebo will be administered to patients to take twice a day for 3 weeks
Study: NCT02473718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid minimization protocol
Description: Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
Study: NCT01856673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Community Group Therapy
Description: It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Standby group
Description: Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
Study: NCT02843711

Intervention type: GENETIC
Intervention: Sequencing
Description: Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
Study: NCT02783781

Intervention type: PROCEDURE
Intervention: Cardiac surgery (extracorporeal circulation; beating heart)
Description: Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection
Study: NCT03425383

Intervention type: DIAGNOSTIC_TEST
Intervention: FMD and c-IMT
Description: The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position.

Intervention type: DIAGNOSTIC_TEST
Intervention: FMD and c-IMT
Description: The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position.
Study: NCT01812161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture protocol 1
Description: Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture protocol 2
Description: Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
Study: NCT02473718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study: NCT02662933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bedside assessment
Description: The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization.
Study: NCT01521481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple inguinal nerve block.
Description: Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral subarachnoid anesthesia
Description: Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
Study: NCT00652977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ritgens maneuver
Description: Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care (Manual support of the perineum)
Description: The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
Study: NCT04446676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization with stem
Description: In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilization with sleeve
Description: In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.
Study: NCT01498939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
Study: NCT02663960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fixed citrate doses protocol
Description: fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: adjusted citrate doses protocol
Description: the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
Study: NCT00633451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercise
Description: Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
Study: NCT02812121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord blood mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord blood mesenchymal stem cells
Study: NCT01526694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: It's a corticosteroid.
Study: NCT03405688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Extra blood samples taken for laboratory analysis
Study: NCT01398163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Fermented Dairy Product (test)
Description: Arm 1 - Intervention 1 (probiotics)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-Milk-based non-fermented dairy product(control)
Description: Arm 2 - Intervention 2 (control)
Study: NCT02554890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696)
Description: sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan (LCZ696) matching placebo
Description: matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril matching placebo
Description: enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
Study: NCT04294303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based telemonitoring system
Description: Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional
Description: Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
Study: NCT01423994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker
Description: A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantable loop recorder
Description: The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate \<50 bpm, High Heart Rate \>165 bpm, and Pause \> 3 seconds.
Study: NCT02186821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
Study: NCT00942968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Description: Daily subcutaneous injection 200IU/kg dalteparin
Study: NCT01352234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 160 mg
Description: Capsule containing Acetylsalicylic Acid 160mg pill with lactose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid 80 mg
Description: Capsule containing Acetylsalicylic Acid 80mg pill with lactose
Study: NCT02892942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-F®
Description: 225 to 450 IU/d; from day 2 of menstrual cycle onward

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-F®
Description: 225 to 450 IU/d; from day 2 of menstrual cycle onward

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide®
Description: 0.25 mg/day, starting on day 6 of Gonal-F®.
Study: NCT01273818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin and cefazolin
Description: 80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 1000 mg cefazolin application intravenously 1 hour before operation
Study: NCT02892942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: 0.25 mg/day, starting on day 6 of Gonal-F®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: 1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
Study: NCT01273818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: 80 mg gentamicin application intraoperatively
Study: NCT04164589

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SCENAR 1NT-02.2
Description: The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR 1NT-02.2
Description: The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
Study: NCT01571271

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Lithotripsy
Description: Laser Lithotripsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrohydraulic Lithotripsy
Description: Electrohydraulic Lithotripsy